| __timestamp | Supernus Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 72471000 | 13774000 |
| Thursday, January 1, 2015 | 89204000 | 22479000 |
| Friday, January 1, 2016 | 106010000 | 27388000 |
| Sunday, January 1, 2017 | 137905000 | 35610000 |
| Monday, January 1, 2018 | 159888000 | 49007000 |
| Tuesday, January 1, 2019 | 158425000 | 61139000 |
| Wednesday, January 1, 2020 | 200677000 | 68836000 |
| Friday, January 1, 2021 | 304759000 | 97592000 |
| Saturday, January 1, 2022 | 377221000 | 106903000 |
| Sunday, January 1, 2023 | 336361000 | 120998000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and Supernus Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Supernus Pharmaceuticals saw a staggering 364% increase in SG&A expenses, peaking in 2022. Meanwhile, Vericel Corporation experienced a remarkable 779% rise, highlighting its aggressive expansion strategy.
Supernus Pharmaceuticals consistently outspent Vericel, with its 2023 expenses nearly three times higher. However, Vericel's rapid growth trajectory suggests a strategic focus on scaling operations. This data underscores the dynamic nature of financial management in the pharmaceutical sector, where balancing growth and cost efficiency is key. As these companies continue to evolve, their SG&A trends offer valuable insights into their strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Dr. Reddy's Laboratories Limited and Vericel Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends